Valbenazine

General information

Indicated for: INGREZZA and INGREZZA SPRINKLE are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated for the treatment of adults with: - tardive dyskinesia. ( 1 ) - chorea associated with Huntington’s disease. ( 1 )

Dosing & forms

• Forms/strengths: —
• Frequency: —
• Food: —
• Typical range: 40–80 mg/day

Mechanism (brief)

Vesicular monoamine transporter 2 (VMAT2) inhibitor.

Metabolism & Half‑life

• Metabolism: CYP3A4, 2D6, active metabolite.
• Half‑life: Long (hours).

Therapeutic Drug Monitoring (TDM)

Recommended: No

Monitoring highlights

• —

Sources

• Valbenazine label — DailyMed (2025)